
Pien Huang
Pien Huang is a global health and development reporter on the Science desk. She was NPR's first Reflect America Fellow, working with shows, desks and podcasts to bring more diverse voices to air and online.
She's a former producer for WBUR/NPR's On Point and was a 2018 Environmental Reporting Fellow with The GroundTruth Project at WCAI in Cape Cod, covering the human impact on climate change. As a freelance audio and digital reporter, Huang's stories on the environment, arts and culture have been featured on NPR, the BBC and PRI's The World.
Huang's experiences span categories and continents. She was executive producer of Data Made to Matter, a podcast from the MIT Sloan School of Management, and was also an adjunct instructor in podcasting and audio journalism at Northeastern University. She worked as a project manager for public artist Ralph Helmick to help plan and execute The Founder's Memorial in Abu Dhabi and with Stoltze Design to tell visual stories through graphic design. Huang has traveled with scientists looking for signs of environmental change in Cameroon's frogs, in Panama's plants and in the ocean water off the ice edge of Antarctica. She has a degree in environmental science and public policy from Harvard.
- 'You Can't Treat If You Can't Empathize': Black Doctors Tackle Vaccine Hesitancy
- Coronavirus FAQ: Do Airplane Passengers Not Know There's A Pandemic Going On?
- Air Travelers To U.S. Must Test Negative For COVID-19 Before Boarding
- Trump Administration Changes Course to Speed Up COVID-19 Vaccine Rollout
- Here's How The U.S. Can Jump Start Its Sluggish COVID-19 Vaccine Rollout
- What's The State Of COVID-19 Vaccination In The U.S.?
- Black Doctors Use Social Media To Share Accurate Information About COVID-19 Vaccine
- More Than 1 Million People Have Received COVID-19 Vaccinations
- Older People, Some Essential Workers To Get Vaccines Next, CDC Panel Says
- Revisiting With People Who Got Stuck In Months-Long Wuhan Lockdown
- Challenges Related To The COVID-19 Vaccine Rollout
- CDC Advisers Agree With FDA: COVID-19 Vaccine Is OK For Public Use